630 related articles for article (PubMed ID: 10574178)
21. Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
Yang J; Chen W; Kang D; Lu X; Li X; Liu Z; Huang B; Daelemans D; Pannecouque C; De Clercq E; Zhan P; Liu X
Eur J Med Chem; 2016 Feb; 109():294-304. PubMed ID: 26802545
[TBL] [Abstract][Full Text] [Related]
22. Effect of stereochemistry on the anti-HIV activity of chiral thiourea compounds.
Venkatachalam TK; Mao C; Uckun FM
Bioorg Med Chem; 2004 Aug; 12(15):4275-84. PubMed ID: 15246104
[TBL] [Abstract][Full Text] [Related]
23. 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
Benjahad A; Croisy M; Monneret C; Bisagni E; Mabire D; Coupa S; Poncelet A; Csoka I; Guillemont J; Meyer C; Andries K; Pauwels R; de Béthune MP; Himmel DM; Das K; Arnold E; Nguyen CH; Grierson DS
J Med Chem; 2005 Mar; 48(6):1948-64. PubMed ID: 15771439
[TBL] [Abstract][Full Text] [Related]
24. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles.
Roth T; Morningstar ML; Boyer PL; Hughes SH; Buckheit RW; Michejda CJ
J Med Chem; 1997 Dec; 40(26):4199-207. PubMed ID: 9435891
[TBL] [Abstract][Full Text] [Related]
26. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
[TBL] [Abstract][Full Text] [Related]
27. [d4U]-butyne-[HI-236] as a non-cleavable, bifunctional NRTI/NNRTI HIV-1 reverse-transcriptase inhibitor.
Hunter R; Muhanji CI; Hale I; Bailey CM; Basavapathruni A; Anderson KS
Bioorg Med Chem Lett; 2007 May; 17(9):2614-7. PubMed ID: 17317163
[TBL] [Abstract][Full Text] [Related]
28. Structure--activity relationship studies of 1-(4-chloro-2,5-dimethoxyphenyl)-3-(3-propoxypropyl)thiourea, a non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type-1.
Weitman M; Lerman K; Nudelman A; Major DT; Hizi A; Herschhorn A
Eur J Med Chem; 2011 Feb; 46(2):447-67. PubMed ID: 21159409
[TBL] [Abstract][Full Text] [Related]
29. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
Ren J; Nichols CE; Stamp A; Chamberlain PP; Ferris R; Weaver KL; Short SA; Stammers DK
FEBS J; 2006 Aug; 273(16):3850-60. PubMed ID: 16911530
[TBL] [Abstract][Full Text] [Related]
30. Potent dual anti-HIV and spermicidal activities of novel oxovanadium(V) complexes with thiourea non-nucleoside inhibitors of HIV-1 reverse transcriptase.
D'Cruz OJ; Dong Y; Uckun FM
Biochem Biophys Res Commun; 2003 Mar; 302(2):253-64. PubMed ID: 12604339
[TBL] [Abstract][Full Text] [Related]
31. Pyrimidine thioethers: a novel class of HIV-1 reverse transcriptase inhibitors with activity against BHAP-resistant HIV.
Nugent RA; Schlachter ST; Murphy MJ; Cleek GJ; Poel TJ; Wishka DG; Graber DR; Yagi Y; Keiser BJ; Olmsted RA; Kopta LA; Swaney SM; Poppe SM; Morris J; Tarpley WG; Thomas RC
J Med Chem; 1998 Sep; 41(20):3793-803. PubMed ID: 9748354
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and anti-HIV activity of 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazines (TTDs): a new family of HIV-1 specific non-nucleoside reverse transcriptase inhibitors.
Arranz ME; Díaz JA; Ingate ST; Witvrouw M; Pannecouque C; Balzarini J; De Clercq E; Vega S
Bioorg Med Chem; 1999 Dec; 7(12):2811-22. PubMed ID: 10658585
[TBL] [Abstract][Full Text] [Related]
33. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
Meng G; Liu Y; Zheng A; Chen F; Chen W; De Clercq E; Pannecouque C; Balzarini J
Eur J Med Chem; 2014 Jul; 82():600-11. PubMed ID: 24952305
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
Liu Z; Chen W; Zhan P; De Clercq E; Pannecouque C; Liu X
Eur J Med Chem; 2014 Nov; 87():52-62. PubMed ID: 25240095
[TBL] [Abstract][Full Text] [Related]
36. Rational approaches for the design of effective human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitors.
Ribone SR; Quevedo MA; Madrid M; Briñón MC
J Chem Inf Model; 2011 Jan; 51(1):130-8. PubMed ID: 21133347
[TBL] [Abstract][Full Text] [Related]
37. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
[TBL] [Abstract][Full Text] [Related]
38. Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
Jin K; Yin H; De Clercq E; Pannecouque C; Meng G; Chen F
Eur J Med Chem; 2018 Feb; 145():726-734. PubMed ID: 29353724
[TBL] [Abstract][Full Text] [Related]
39. [d4U]-spacer-[HI-236] double-drug inhibitors of HIV-1 reverse-transcriptase.
Younis Y; Hunter R; Muhanji CI; Hale I; Singh R; Bailey CM; Sullivan TJ; Anderson KS
Bioorg Med Chem; 2010 Jul; 18(13):4661-73. PubMed ID: 20605472
[TBL] [Abstract][Full Text] [Related]
40. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
Ren J; Milton J; Weaver KL; Short SA; Stuart DI; Stammers DK
Structure; 2000 Oct; 8(10):1089-94. PubMed ID: 11080630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
